Medtronic, Inc.  

(Public, NYSE:MDT)   Watch this stock  
Find more results for MDT
+1.47 (1.95%)
Jan 23 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 75.47 - 77.39
52 week 53.33 - 77.39
Open 75.85
Vol / Avg. 23.26M/8.88M
Mkt cap 75.74B
P/E 26.56
Div/yield 0.31/1.59
EPS 2.90
Shares 984.32M
Beta 1.07
Inst. own 99%
Feb 17, 2015
Q3 2015 Medtronic Inc Earnings Release - 9:30AM EST - Add to calendar
Jan 12, 2015
Medtronic Inc at JPMorgan Healthcare Conference
Jan 6, 2015
Medtronic Inc Extraordinary Shareholders Meeting
Dec 10, 2014
Medtronic Inc. at Oppenheimer Healthcare Conference - Webcast
Nov 18, 2014
Q2 2015 Medtronic Inc Earnings Release
Nov 18, 2014
Q2 2015 Medtronic Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '14) 2014
Net profit margin 18.96% 18.02%
Operating margin 25.45% 22.42%
EBITD margin - 33.33%
Return on average assets 8.70% 8.42%
Return on average equity 17.17% 16.08%
Employees 49,000 -
CDP Score - 61 D


United States - Map
+1-763-5144000 (Phone)
+1-763-5144879 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Medtronic, Inc. (Medtronic) is a medical technology company. The Company provides products and therapies for use by medical professionals to meet the healthcare needs of their patients. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat and diabetes conditions. Medtronic operates through three segments that manufacture and sells device-based medical therapies. Its operating segments are Cardiac and Vascular Group, which consists of Cardiac Rhythm Disease Management (CRDM), Coronary, Structural Heart and Endovascular; Restorative Therapies Group, which consists of Spine, Neuromodulation and Surgical Technologies, and Diabetes Group. In January 2014, the Company acquired TYRX, Inc. In July 2014, it acquired Visualase, Inc. Effective August 27, 2014, the Company acquired the remaining 70% interest in NGC Medical SpA.

Officers and directors

Omar Ishrak Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Gary L. Ellis Chief Financial Officer, Senior Vice President
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Carol A. Surface Chief Human Resource Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Michael J. Coyle Executive Vice President, Group President - Cardiac and Vascular Group
Age: 51
Bio & Compensation  - Reuters
Hooman C. Hakami Executive Vice President and Group President of the Medtronic Diabetes Group
Age: 44
Bio & Compensation  - Reuters
Robert ten Hoedt Executive Vice President and President, EMEAC
Age: 53
Bio & Compensation  - Reuters
Christopher J. O'Connell Executive Vice President and Group President - Restorative Therapies Group
Age: 47
Bio & Compensation  - Reuters
Richard E. Kuntz M.D. Senior Vice President, Chief Scientific, Clinical and Regulatory Officer
Age: 57
Bio & Compensation  - Reuters
Bradley E. Lerman Senior Vice President, General Counsel, Corporate secretary
Age: 57
Bio & Compensation  - Reuters
Geoffrey S. Martha Senior Vice President - Strategy and Business Development
Age: 44
Bio & Compensation  - Reuters